Kintara Therapeutics (KTRA) Gets a Buy Rating from Maxim Group


In a report released yesterday, Jason McCarthy from Maxim Group reiterated a Buy rating on Kintara Therapeutics (KTRA), with a price target of $6.00. The company’s shares closed last Thursday at $2.50.

According to TipRanks.com, McCarthy is a top 25 analyst with an average return of 79.5% and a 73.2% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Appili Therapeutics Inc Class A, Brainstorm Cell Therapeutics, and SELLAS Life Sciences Group.

Currently, the analyst consensus on Kintara Therapeutics is a Moderate Buy with an average price target of $5.50.

See today’s analyst top recommended stocks >>

Kintara Therapeutics’ market cap is currently $76.57M and has a P/E ratio of -1.10. The company has a Price to Book ratio of -16.87.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

DelMar Pharmaceuticals, Inc. is a clinical and biopharmaceutical company, which focuses on the development and commercialization of new cancer therapies. It pipeline includes the VAL-083. The company was founded by Jeffrey A. Bacha, Dennis M. Brown, and William J. Garner on June 24, 2009 and is headquartered in San Diego, CA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts